FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2810071907> ?p ?o ?g. }

• W2810071907 abstract "Altered gut microbiota are assumed to be involved in the pathogenesis of irritable bowel syndrome (IBS). However, gut microbiota alterations reported in different studies are divergent and sometimes even contradictory. To better elucidate the relationship between altered gut microbiota and IBS, we characterized fecal microbiota of diarrhea-predominant IBS (IBS-D) patients and further explored the effect of rifaximin on gut microbiota using bacterial 16S rRNA gene-targeted pyrosequencing. In our study, IBS-D patients defined by Rome III criteria and age-and-gender matched healthy controls (HC) were enrolled to investigate the fecal microbiota alterations. These IBS-D patients were then treated with rifaximin for 2 weeks and followed up for 10 weeks. Fecal microbiota alterations, small intestine bacterial overgrowth (SIBO) and gastrointestinal (GI) symptoms of IBS-D patients were analyzed before and after treatment. Our results showed fecal microbiota richness but not diversity was decreased in IBS-D patients as compared to HC and there were alterations of fecal microbiota at different taxonomy levels. The abundant phyla Firmicutes was significantly decreased and Bacteroidetes was increased in IBS-D patients. Moreover, the alterations of predominant fermenting bacteria such as Bacteroidales and Clostridiales might be involved in the pathophysiology of IBS-D. In addition, rifaximin was effective in terms of SIBO eradication and even GI symptoms of IBS-D patients achieved at least 10-week improvement after treatment. Furthermore, rifaximin induced alterations of some special bacteria rather than affected the overall composition of microbiota in IBS-D patients. Meanwhile, a potential decrease in propanoate and butanoate metabolism was found in these IBS-D patients after rifaximin treatment. Taken together, there were alterations of gut microbiota in IBS-D patients as compared to HC. Rifaximin could relieve GI symptoms, modify gut microbiota in IBS-D patients and eradicate SIBO in those patients with SIBO, suggesting an additional therapeutic mechanism of rifaximin in the treatment of IBS-D. Our findings of compositional gut microbiota alterations in IBS-D and the effect of rifaximin on the gut microbiota implied that altered gut microbiota were associated with the pathogenesis of IBS." @default.
• W2810071907 created "2018-07-10" @default.
• W2810071907 creator A5003829221 @default.
• W2810071907 creator A5003861058 @default.
• W2810071907 creator A5027475930 @default.
• W2810071907 creator A5029757714 @default.
• W2810071907 creator A5038198349 @default.
• W2810071907 creator A5076035375 @default.
• W2810071907 date "2018-07-25" @default.
• W2810071907 modified "2023-10-14" @default.
• W2810071907 title "Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome" @default.
• W2810071907 cites W1487811474 @default.
• W2810071907 cites W1587016945 @default.
• W2810071907 cites W1974577714 @default.
• W2810071907 cites W1994698278 @default.
• W2810071907 cites W2025873491 @default.
• W2810071907 cites W2053176597 @default.
• W2810071907 cites W2086580205 @default.
• W2810071907 cites W2104251890 @default.
• W2810071907 cites W2110300022 @default.
• W2810071907 cites W2113582196 @default.
• W2810071907 cites W2120356061 @default.
• W2810071907 cites W2121782849 @default.
• W2810071907 cites W2123812491 @default.
• W2810071907 cites W2133715751 @default.
• W2810071907 cites W2133856765 @default.
• W2810071907 cites W2135255921 @default.
• W2810071907 cites W2144750725 @default.
• W2810071907 cites W2149216059 @default.
• W2810071907 cites W2176306270 @default.
• W2810071907 cites W2194277343 @default.
• W2810071907 cites W2403829688 @default.
• W2810071907 cites W2409865253 @default.
• W2810071907 cites W2438251162 @default.
• W2810071907 cites W2513213841 @default.
• W2810071907 cites W2560075974 @default.
• W2810071907 cites W2574577991 @default.
• W2810071907 cites W2578484558 @default.
• W2810071907 cites W2601263590 @default.
• W2810071907 cites W76134149 @default.
• W2810071907 doi "https://doi.org/10.3389/fmicb.2018.01600" @default.
• W2810071907 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6068233" @default.
• W2810071907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30090090" @default.
• W2810071907 hasPublicationYear "2018" @default.
• W2810071907 type Work @default.
• W2810071907 sameAs 2810071907 @default.
• W2810071907 citedByCount "83" @default.
• W2810071907 countsByYear W28100719072019 @default.
• W2810071907 countsByYear W28100719072020 @default.
• W2810071907 countsByYear W28100719072021 @default.
• W2810071907 countsByYear W28100719072022 @default.
• W2810071907 countsByYear W28100719072023 @default.
• W2810071907 crossrefType "journal-article" @default.
• W2810071907 hasAuthorship W2810071907A5003829221 @default.
• W2810071907 hasAuthorship W2810071907A5003861058 @default.
• W2810071907 hasAuthorship W2810071907A5027475930 @default.
• W2810071907 hasAuthorship W2810071907A5029757714 @default.
• W2810071907 hasAuthorship W2810071907A5038198349 @default.
• W2810071907 hasAuthorship W2810071907A5076035375 @default.
• W2810071907 hasBestOaLocation W28100719071 @default.
• W2810071907 hasConcept C126322002 @default.
• W2810071907 hasConcept C203014093 @default.
• W2810071907 hasConcept C2777385719 @default.
• W2810071907 hasConcept C2777695942 @default.
• W2810071907 hasConcept C2778271842 @default.
• W2810071907 hasConcept C2778889925 @default.
• W2810071907 hasConcept C2779802037 @default.
• W2810071907 hasConcept C2780206646 @default.
• W2810071907 hasConcept C2780305828 @default.
• W2810071907 hasConcept C2780999109 @default.
• W2810071907 hasConcept C42062724 @default.
• W2810071907 hasConcept C501593827 @default.
• W2810071907 hasConcept C523546767 @default.
• W2810071907 hasConcept C539455810 @default.
• W2810071907 hasConcept C54355233 @default.
• W2810071907 hasConcept C61716771 @default.
• W2810071907 hasConcept C71924100 @default.
• W2810071907 hasConcept C86803240 @default.
• W2810071907 hasConcept C89423630 @default.
• W2810071907 hasConcept C90924648 @default.
• W2810071907 hasConceptScore W2810071907C126322002 @default.
• W2810071907 hasConceptScore W2810071907C203014093 @default.
• W2810071907 hasConceptScore W2810071907C2777385719 @default.
• W2810071907 hasConceptScore W2810071907C2777695942 @default.
• W2810071907 hasConceptScore W2810071907C2778271842 @default.
• W2810071907 hasConceptScore W2810071907C2778889925 @default.
• W2810071907 hasConceptScore W2810071907C2779802037 @default.
• W2810071907 hasConceptScore W2810071907C2780206646 @default.
• W2810071907 hasConceptScore W2810071907C2780305828 @default.
• W2810071907 hasConceptScore W2810071907C2780999109 @default.
• W2810071907 hasConceptScore W2810071907C42062724 @default.
• W2810071907 hasConceptScore W2810071907C501593827 @default.
• W2810071907 hasConceptScore W2810071907C523546767 @default.
• W2810071907 hasConceptScore W2810071907C539455810 @default.
• W2810071907 hasConceptScore W2810071907C54355233 @default.
• W2810071907 hasConceptScore W2810071907C61716771 @default.
• W2810071907 hasConceptScore W2810071907C71924100 @default.
• W2810071907 hasConceptScore W2810071907C86803240 @default.
• W2810071907 hasConceptScore W2810071907C89423630 @default.
• W2810071907 hasConceptScore W2810071907C90924648 @default.

• next